A study published in Cell Reports by researchers at Rutgers University identifies the presence of senescent CD8+ T cells in patients as a factor contributing to poor outcomes in CAR T-cell therapy.
Key Findings
- The study focused on CD8+ T cells, which are used to manufacture CAR T-cell therapies.
- T cells from donors with high levels of senescence expanded less effectively under standard culture conditions.
- Analysis of clinical data from lymphoma patients showed that those with stronger senescence signatures in their starting T cells or finished products were more likely to fail treatment.
- The study suggests that senescence, not chronological age, is the primary driver of molecular differences in T cell function.
Mechanism
Senescent T cells stop dividing but do not die, releasing inflammatory molecules that contribute to chronic inflammation.
The researchers identified transcription factors controlling the senescence program. They found that reducing their levels partially restored gene expression patterns associated with normal T cell activation, though recovery of cell division was modest.
Implications
- The findings may help predict which patients will respond to CAR T-cell therapy.
- The research connects to broader aging biology, as senescent immune cells accumulate with age and are linked to chronic inflammation and various diseases.
- The study was retrospective and requires confirmation in prospective clinical trials.